Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia

Blood

Volumn 89, Issue 6, 1997, Pages 1886-1895

  Parsons, Susan K ^a   Skapek, Stephen X ^b   Neufeld, Ellis J ^b   Kuhlman, Caroline ^b   Young, Mary L ^b   Donnelly, Mia ^b   Brunzell, John D ^b   Otvos, James D ^b   Sallan, Stephen E ^b   Rifai, Nader ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ASPARAGINASE; CHOLESTEROL; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INTRATHECAL DRUG ADMINISTRATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0030937246     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.1886     Document Type: Article

References (33)

1. Broome JD: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I and II. J Exp Med 118:99, 1963
2. Hill JM, Roberts J, Loeb E, MacLellan HA, Hill RW: L-asparaginase therapy for leukemia and other malignant neoplasms. JAMA 202:882, 1967
3. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657, 1986
4. Asselin B, Gelber R, Sallan S: Relative toxicity of E. coli L-asparaginase (ASP) and pegaspargase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL). Blood 86:695a, 1995 (abstr, suppl 1)
5. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M: Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 83:386, 1994
6. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F, and the GIMEMA Group: Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: A retrospective study. Eur J Haematol 49:63, 1992
7. Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, Murphy ML, Borchenal JH: Toxicity of E. coli L-asparaginase in man. Cancer 25:253, 1970
8. Zollner N, Heimstadt P: Effects of a single administration of L-asparaginase on serum lipids. Nutr Metabol 13:344, 1971
9. Cremer P, Lakomek M, Beck W, Prindull G: The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukemia. Eur J Pediatr 147:64, 1988
10. Favrot MC, Dallamonica C, Soullet G: Study of blood lipids in 30 children with a malignant hematological disease or carcinoma Biomed Pharmacother 37:55, 1983
11. Steinherz PG: Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer 74:3234, 1994
12. Glueck CJ, Kaplan AP, Levy RI, Greten H, Gralnick H, Fredrickson DS: A new mechanism of exogenous hypertriglyceridemia. Ann Intern Med 71:1051, 1969
13. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK: Plasma lipid alterations in leukemia and lymphoma. Am J Med 72:775, 1982
14. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK: Fluorescence polarization as a parameter of plasma lipids in patients with hematologic malignancies. Leuk Res 7:647, 1983
15. NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents: National Cholesterol Education Program (NCEP): Highlights of the report of the Expert Panel on Blood Cholestrol Levels in Children and Adolescents. Pediatrics 89:495, 1992
16. ++ precipitation for quantitation of high density lipoprotien cholesterol. Clin Chem 28:1379, 1982
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem 18:449, 1972
18. The Lipid Research Clinics Population Studies Data Book, Vol I: The Prevalence Study. NIH Publication No. 80-1527. Bethesda, MD, National Institutes of Health, 1980
19. Schaefer EJ, Levy RI: Pathogenesis and management of lipoprotein disorders. N Engl J Med 312:1300, 1985
20. Rifai N, Neufeld E, Ahlstrom P, Rimm E, D'Angelo L, Hicks JM: Failure of current guidelines for cholesterol screening in urban African American adolescents. Pediatrics 98:383, 1996
21. Marcovina SM, Albers JJ, Henderson LO, Hannon WH: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins AI and B. III. Comparability of apolipoprotein AI values by use of international reference material. Clin Chem 39:773, 1993
22. Marcovina SM, Albers JJ. Kennedy H, Mei JV, Henderson LO, Hannon WH: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins AI and B. IV. Comparability of apolipoprotein B values by use of interntional reference material. Clin Chem 40:586, 1994
23. Otvos JD, Jeyarajah FJ, Bennett DW, Krauss RM: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38:1632, 1992
24. Otvos JD: Determination of lipoproteins and their subfractions by nuclear magnetic resonance, in Rifai N, Warnick GR (eds): Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins. Washington, DC, AACC, 1994, p 329
25. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD: Detection and characterization of heterogeneous state for lipoprotein lipase deficiency. Arteriosclerosis 9:326, 1990
26. Ma YT, Bruin S, Tuzgol RI, Wilson G, Roederer MS: Two naturally occuring mutations at the first and second bases of codon aspartic acid 156 in the proposed catalytic triad of human lipoprotein lipase: In vivo evidence that aspartic acid 156 is essential for catalysis. J Biol Chem 267:1918, 1992
27. Iverius PH, Brunzell JD: Human adipose tissue lipoprotein lipase: Changes with feeding and relationship to postheparin plasma enzyme. Am J Physiol 249:E107, 1985
28. Kammel WB, Castelli WP, Gordon P: Cholesterol in the prediction of atherosclerotic disease: New perspectives from the Framingham Study. Ann Intern Med 90:85, 1979
29. Brunzell JD, Schrott HG: The interaction of familial and secondary causes of hypertriglyceridemia: Role in pancreatitis. Trans Assoc Am Physicians 86:245, 1973
30. Brown SA, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 34:232, 1986
31. Austin MA, Hokanson JE, Brunzell JD: Measurement and clinical significance of low-density lipoprotein subclasses, in Rifai N, Warnick GR (eds): Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC, AACC, 1994, p 223
32. Dessi A, Batetta B, Spano O, Sanna F, Tonello M, Giacchino M, Tessitore L, Costelli P, Baccino F, Madon E, Pani P: Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. Clin Sci 89:505, 1995
33. Talvensaari KK, Lanning M, Tapanainen P, Knip M: Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 81:3051, 1996